Inside the research
Corcept Therapeutics Incorporated
CORT Research profile · latest available data
Price overview
$116.10
▼ -2.41 (-2.0%)
| 52w hi | $123.57 |
|---|---|
| 52w lo | $32.15 |
| Vol | 800.80K |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.40
| Short | +0.34 |
|---|---|
| Medium | +0.51 |
| Long | +0.29 |
computed 2026-09-27
Key fundamentals
Corcept Therapeutics Incorporated
Healthcare · Biotechnology
| Market cap | $12.55B |
|---|---|
| Enterprise value | $12.25B |
| Trailing P/E | 258.00x |
| Forward P/E | 26.37x |
| EV / EBITDA | 1515.52x |
| P / S (ttm) | 15.11x |
| Profit margin | 6.6% |
| Return on equity | 8.2% |
| Revenue growth | +31.7% |
| Earnings growth | +24.1% |
| Debt / equity | 1.33 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.21 | |
| Sector | +0.08 | |
| Technical | +0.27 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Risk Metrics
| Beta vs SPX | 1.41 |
|---|---|
| Corr SPX | 0.22 |
| Annual vol | 103.1% |
| Annual ret | +95.0% |
| Sharpe | 0.92 |
| Max DD | -71.9% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-29 | Earnings Release, Reg FD Disclosure… | read |
| 2026-06-17 | Other Material Event, Exhibits | read |
| 2026-06-03 | Other Material Event | read |
| 2026-05-28 | Officer / Director Change, Shareholder Vote… | read |
| 2026-04-30 | Earnings Release, Reg FD Disclosure… | read |
| 2026-03-25 | Other Material Event, Exhibits | read |
| 2026-02-24 | Earnings Release, Reg FD Disclosure… | read |
| 2026-02-19 | Other Material Event, Exhibits | read |
| 2026-01-22 | Other Material Event, Exhibits | read |
| 2025-12-31 | Other Material Event, Exhibits | read |
| 2025-11-04 | Earnings Release, Reg FD Disclosure | read |
| 2025-10-14 | Termination of Agreement, Exhibits | read |
SEC Filings
The Long Run
FY 2011–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $675.04M | +105.1% | |
| Gross profit | $85.11M | +78.5% | |
| Operating income | $107.28M | +34.2% | |
| Net income | $106.14M | +51.1% | |
| Cash from ops | $198.29M | +40.5% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $119.00 | $120.44 | $114.51 | $116.10 | 800.80K |
| Sep 24 | $111.86 | $119.15 | $111.68 | $118.51 | 983.60K |
| Sep 23 | $117.33 | $118.79 | $112.05 | $112.94 | 809.80K |
| Sep 22 | $113.96 | $119.00 | $113.09 | $117.51 | 810.20K |
| Sep 21 | $110.29 | $116.65 | $109.00 | $113.76 | 1.35M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →